sellWeak cluster of 410b5-1 plan
Jane Henderson sold $132k of APGE
Chief Financial Officer at Apogee Therapeutics, Inc.. 2,000 shares at an average of $65.81, traded Feb 2, 2026, filed Feb 4, 2026.
Warning score
28Value
$132k
2,000 shares
Holdings after
183,371
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +11Trade size$132k at market
- 0Share of holdings soldSold 1.1% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-26-010453, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -792 | $65.21 | $52k | 184,579 | Feb 4, 2026 |
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -1,108 | $66.15 | $73k | 183,471 | Feb 4, 2026 |
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $66.89 | $6,689 | 183,371 | Feb 4, 2026 |
Related signals
Other insiders at Apogee Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $170k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.5M 20,000 shares | -2% | |
| 11Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $391k 5,500 shares | -3% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $140k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.3M 20,000 shares | -2% | |
| 10Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $362k 5,500 shares | -3% | |
| 75Notable | Apogee Therapeutics, Inc. | Fairmount Funds Management LLC director | $134M 1,750,000 shares | -85% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.6M 20,000 shares | -2% | |
| 20Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $1.5M 18,700 shares | -8% | |
| 37Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $609k 8,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.